Comments on After an interim analysis, CureVac defends its vaccine Although an interim analysis showed that the CureVac vaccine was only 47 percent effective, company boss Haas does not want to know anything about a failure. He is hoping for further tests so that the vaccine will be ready for the market after all.

Comments on After an interim analysis, CureVac defends its vaccine Although an interim analysis showed that the CureVac vaccine was only 47 percent effective, company boss Haas does not want to know anything about a failure. He is hoping for further tests so that the vaccine will be ready for the market after all. Spress is a general newspaper in English which is updated 24 hours a day. 2021-06-22T22:35:17Z https://en.spress.net/after-an-interim-analysis-curevac-defends-its-vaccine-although-an-interim-analysis-showed-that-the-curevac-vaccine-was-only-47-percent-effective-company-boss-haas-does-not-want-to-know-anything-abou/feed/atom/